source
- Alnylam shares tumble nearly 30% after cutting revenue outlook for key amyloidosis drugsAlnylam Pharmaceuticals saw its market value drop about 30%, roughly $12 billion, after it lowered its revenue forecast for its leading amyloidosis treatments. The company had previously expected…
- FDA advisory panel rejects Capricor's Duchenne heart-cell therapy deramiocelAn FDA advisory committee voted 9-3 to reject Capricor Therapeutics' experimental cell therapy deramiocel for Duchenne-related cardiomyopathy. The panel said the data did not provide substantial ev…